Penalised for having cancer

1 November 2012 0

Many cancer patients are being tipped into poverty as a direct result of their illness, which adds stress and misery to an already very difficult situation. In this editorial, Cancer World looks at the many [more]

Many cancer patients are being tipped into poverty as a direct result of their illness, which adds stress and misery to an already very difficult situation. In this editorial, Cancer World looks at the many ways that a having...... [ more ]

Andreas Engert: Learning from Hodgkin’s

1 November 2012 0

Hodgkin’s patients survive for longer – but with more serious and lasting damage – than almost any other group of cancer patients. Finding ways to address the problems of both current and future survivors can [more]

Hodgkin's patients survive for longer – but with more serious and lasting damage – than almost any other group of cancer patients. Finding ways to address the problems of both current and future survivors can provide valuable...... [ more ]

Testing the testers

1 November 2012 0

Treating the right patient with the right therapy at the right time depends on having the right picture of every patient’s key biological markers. A number of initiatives are now springing up across Europe to [more]

Treating the right patient with the right therapy at the right time depends on having the right picture of every patient's key biological markers. A number of initiatives are now springing up across Europe to ensure that...... [ more ]

Late diagnosis: Why does it happen? How can we do better?

1 November 2012 0

When GPs fail to identify symptomatic cancers on time it can be fatal for patients and frustrating for the specialists who treat them. In this article, GP Tina Eriksson and gastrointestinal cancer specialist Eric Van [more]

When GPs fail to identify symptomatic cancers on time it can be fatal for patients and frustrating for the specialists who treat them. In this article, GP Tina Eriksson and gastrointestinal cancer specialist Eric Van Cutsem...... [ more ]

The origin of a special success

1 November 2012 0

Cancer genetics is intriguing, exciting and offers hope for real progress in treatment, but try telling that to non-scientists. Clive Cookson, science editor at the Financial Times, did just that. His article, explaining the evolutionary [more]

Cancer genetics is intriguing, exciting and offers hope for real progress in treatment, but try telling that to non-scientists. Clive Cookson, science editor at the Financial Times, did just that.... [ more ]

OECI accreditation: is yours a top-class cancer centre?

1 November 2012 0

Whether you work at a cancer unit, a cancer centre or a comprehensive cancer centre, applying for OECI accreditation is a good way to find out how your institute compares with the best, and get [more]

Whether you work at a cancer unit, a cancer centre or a comprehensive cancer centre, applying for OECI accreditation is a good way to find out how your institute compares with the best, and get advice on how to address any...... [ more ]

Lungscape: a living lung laboratory

1 November 2012 0

The potential for personalising lung cancer therapies is expanding rapidly. The challenge now is how to turn that potential into reality as fast as possible so patients can reap the benefits. A network of cancer [more]

The potential for personalising lung cancer therapies is expanding rapidly. The challenge now is how to turn that potential into reality as fast as possible so patients can reap the benefits.... [ more ]

Gastro-oesophageal cancer –is CROSSing over so hard to do?

1 November 2012 0

Suboptimal studies had established preoperative chemoradiation as the preferred strategy in the management of localised oesophageal cancer (LEC) and gastro-oesophageal cancer. The recent CROSS trial has now demonstrated considerable benefit from preoperative chemoradiation over surgery [more]

Suboptimal studies had established preoperative chemoradiation as the preferred strategy in the management of localised oesophageal cancer (LEC) and gastro-oesophageal cancer. ... [ more ]

Cetuximab dosing by rash ­– is the scaling of EVEREST meaningful?

1 November 2012 0

The small EVEREST trial has shown that the concept of guiding cetuximab dose escalation using the clinical parameter of acneiform skin rash is safe. However, as no significant increase of cetuximab efficacy could be observed, [more]

The small EVEREST trial has shown that the concept of guiding cetuximab dose escalation using the clinical parameter of acneiform skin rash is safe. However, as no significant increase of cetuximab efficacy could be observed...... [ more ]

Newsround

1 November 2012 0

Selected reports edited by Janet Fricker Glioblastoma: temozolomide offers alternative to radio-therapy in elderly patients => The Lancet Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options for elderly patients with glioblastoma, [more]

Selected reports edited by Janet Fricker... [ more ]

My World

1 November 2012 0

Maria João Cardoso is head breast surgeon at the Champalimaud Cancer Centre in Lisbon. She founded the patient support centre Mama Help, and leads a research group at the Institute for Systems and Computer Engineering, [more]

Maria João Cardoso is head breast surgeon at the Champalimaud Cancer Centre in Lisbon. She founded the patient support centre Mama Help, and leads a research group at the Institute for Systems and Computer Engineering, in Porto...... [ more ]